Sonoran Biosciences has received a Phase 1 SBIR award from the National Institutes of Health for $259,613
TEMPE, Ariz., Sep. 6, 2022 — Sonoran Biosciences, a preclinical-stage pharmaceutical company developing innovative hospital-based products for the treatment of surgical site infections and postoperative pain, has been awarded a $259,613 Small Business Innovation Research (SBIR) Phase I grant by the National Institute of General Medical Sciences of the National Institutes of Health. The project’s title is “Sustained-release gel for multi-day control of postoperative pain.”
The project is focused on establishing feasibility of SBG004, an extended-release formulation of bupivacaine using Sonoran’s SB Gel, as a best-in-class extended-release local anesthetic for treatment of acute postoperative pain lasting at least 72 hr. SBG004 provides local release of bupivacaine for 7-14 days to reversibly block conduction of pain impulses from the tissues around a surgical site. The major goals of the project are to: i) complete activities to prepare for manufacturing scale-up of SBG004; ii) evaluate analgesic efficacy of SBG004 in soft and hard tissue models of postoperative pain; and iii) characterize pharmacokinetics, toxicity, and local tolerability of SBG004.
About Sonoran Biosciences
Sonoran Biosciences, Inc. is a privately held specialty pharmaceutical company developing sustained release formulations for the treatment of postoperative pain and surgical site infection (SSI). Sonoran’s products are based on its proprietary SB Gel, an injectable carrier that forms a solid gel in the body, releases drugs over multiple days, and dissolves after the drugs are released. Sonoran’s lead products are SBG004, a long-acting formulation of bupivacaine for postoperative pain, and SBG003, a fixed-dose combination of tobramycin and vancomycin for surgical site infection.
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.